Literature DB >> 3929265

Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.

F M Debruyne, H F Karthaus, F H Schröder, H J de Voogt, F H de Jong, J G Klijn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3929265

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN： 0361-7742


× No keyword cloud information.
  2 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients.

Authors:  J H Blom; W H Hirdes; F H Schröder; F H de Jong; D J Kwekkeboom; A J van't Veen; J Sandow; B Krauss
Journal:  Urol Res       Date:  1989
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.